1 / 13

Clinical Description William Sacks, PhD, MD—ODE/CDRH

R2 Technology, Inc. ImageChecker CT CAD Software System P030012 Radiological Devices Advisory Panel February 3, 2004. Clinical Description William Sacks, PhD, MD—ODE/CDRH. Outline Character of device Clinical utility Instructions for use Issues new to this PMA.

mignon
Download Presentation

Clinical Description William Sacks, PhD, MD—ODE/CDRH

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. R2 Technology, Inc. ImageChecker CT CAD Software SystemP030012 Radiological Devices Advisory Panel February 3, 2004 Clinical Description William Sacks, PhD, MD—ODE/CDRH Sacks

  2. Outline • Character of device • Clinical utility • Instructions for use • Issues new to this PMA Sacks

  3. Character of device • For chest CT scans • For CTs done for any indication • Detects solid lung nodules • E.g., not ground glass opacities (GGOs) • Nodules between 4-30 mm • Computer-Aided Detection (CAD) Sacks

  4. Computer-Aided Detection(CAD)/Diagnosis(CADx) CAD CADx Sacks

  5. Clinical Utility • Many nodules missed in clinical practice: • other pathology distracts • hundreds of images per exam • CAD intended to reduce missed nodules; i.e., intended to increase user’s SENSITIVITY to detecting lung nodules Sacks

  6. Instructions for Use • Reader reviews films unaided first • CAD marks candidate nodules • Reader looks again in vicinity of marks • If CAD fails to mark a nodule judged actionable on unaided review, reader should retain initial judgment Sacks

  7. Issues new to this PMA • CAD target • Definition of “truth” • Unit of analysis • Endpoints Sacks

  8. CAD TARGET • Not malignant nodule • but • Actionable nodule Sacks

  9. DEFINITION OF “TRUTH” • Not biopsy (tissue histology) • but • Expert panel Sacks

  10. UNIT OF ANALYSIS • Statistical unit = person • further broken down into • Lung quadrant Sacks

  11. ENDPOINTS • Sensitivity and specificity (or FPF) of action recommendationand/or ROC Sacks

  12. CLINICAL STUDY • 3 expert radiologists on panel to determine “truth” for each nodule • 15 other radiologists with range of experience, called “the readers” • 90 subjects (360 lung quadrants) • 15 readers used 100-point scale for confidence-in-actionability of each case Sacks

  13. CLINICAL STUDY • Presentation by • Nicholas Petrick, Ph.D. • OST/CDRH Sacks

More Related